AU Patent

AU2010333039A1 — Pharmaceutical composition for treatment of dry eye syndrome

Assigned to Novaliq GmbH · Expires 2012-07-12 · 14y expired

What this patent protects

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosupp…

USPTO Abstract

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010333039A1
Jurisdiction
AU
Classification
—
Expires
2012-07-12
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.